

Ringversuch: **CoVimm2/21**
im Monat: **Oktober 2021**
Teilnehmer-Nr.: **0000072**
ausgestellt am: **30.10.21**



Referenzinstitut für Bioanalytik

Klinikum rechts der Isar der TU München
Institut für Klinische Chemie
und Pathobiochemie
Endokrinologie/immunologie
Ismaninger Str. 22
81675 München



Ringversuchsleiter

Prof. Dr. C. Knabbe
Prof. Dr. Dr. K.P. Kohse
Prof. Dr. M. Neumaier

Leitung RfB

Dr. W. J. Geilenkeuser
Dr. A. Kessler

Bonn, 20. Dezember 2021

Teilnahmebescheinigung

Wir bestätigen, daß Sie am Ringversuch zur SARS-CoV-2 Serologie teilgenommen haben.

Anti-CoV IgG total

Wass. p. Kohse M.J. Geilenkeuser A. Kessler

Sars-CoV-2 Immunologie 2/21 - Auswertung

- Ihre Ergebnisse sind mit farbigen Punkten gekennzeichnet -
(grün-richtig, gelbgrün-bedingt richtig, rot-falsch, grau-Ihre Methode(n))

- Probe 1 34-year-old asymptomatic patient who tested positive for SARS-CoV-2 by qRT-PCR and was treated as an outpatient. Blood sampling was performed 50 days after infection. Detection of anti-S-SARS-CoV-2 IgG without neutralizing activity. No detection of anti-N-SARS-CoV-2 IgG.
- Probe 2 65-year-old symptomatic patient who tested positive for SARS-CoV-2 by qRT-PCR and was treated as an outpatient. Blood sampling was performed 238 days after infection. Detection of anti-S-SARS-CoV-2 IgG without neutralizing activity in the diluted sample (1:1.3) dispatched in this EQA. Furthermore, detection of anti-N-SARS-CoV-2 IgG.
- Probe 3 SARS-CoV-2 negative patient pool consisting of serum from healthy blood donors with no clinical evidence of SARS-CoV-2 infection in the past. Antibodies were neither detected by the use of various immunoassays nor in the micro-NAT
- Probe 4 38-yr-old patient, no clinical evidence of a SARS-CoV-2 infection in the previous five months. The patient was vaccinated twice (mRNA vaccine). Blood sampling 87 d after 2nd vaccination. Detection of anti-S-SARS-CoV-2 IgG with neutralizing activity against WT SARS-CoV-2, but without neutralizing activity against delta variant. No detection of anti-N-SARS-CoV-2 IgG.

Anti-N-CoV IgG

Erfolgsquote 50/51 => 98 %

Benutzte Systeme:

n(r) n(br) n(f)

Ergebnisse	positiv/ reaktiv	grenzwertig	negativ
Probe 1	1	4	46
Probe 2	33	3	15
Probe 3	0	0	51
Probe 4	1	0	50

Roche(30)	Cobas(5)	18	4
Abbott(4)	Architect(1)	1	6
Abbott(4)	Alinity(38)	0	3
Roche(30)	Elecsys(6)	3	
Euroimmun(5)	manuell(98)	1	1
Andere, others(99)	andere(99)	1	1
Mikrogen(181)	andere(99)	2	1
Bio-Rad(2)	andere(99)	1	
Abbott(4)	Schnelltest(97)	0	1
Euroimmun(5)	Analyzer I(28)	0	1
Euroimmun(5)	DSX(29)	0	1
Euroimmun(5)	Eurolab Workstation(37)	0	1
Euroimmun(5)	andere(99)	0	1
IBL(41)	manuell(98)	1	
SERAMUN Diagnostica(60)	manuell(98)	1	
Andere, others(99)	Tecan Sunrise(33)	0	1
AESKU.Diagnostics(139)	andere(99)	0	1
Mikrogen(181)	manuell(98)	1	
Viramed Biotech(189)	andere(99)	1	